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Abstract
Degradation of the extracellular matrix (ECM), a critical step in cancer metastasis, is determined by the balance between
MMPs (matrix metalloproteinases) and their inhibitors TIMPs (tissue inhibitors of metalloproteinases). In cancer cells, this
balance is shifted towards MMPs, promoting ECM degradation. Here, we show that EZH2 plays an active role in this process
by repressing the expression of TIMP2 and TIMP3 in prostate cancer cells. The TIMP genes are derepressed by knockdown of
EZH2 expression in human prostate cancer cells but repressed by overexpression of EZH2 in benign human prostate
epithelial cells. EZH2 catalyzes H3K27 trimethylation and subsequent DNA methylation of the TIMP gene promoters.
Overexpression of EZH2 confers an invasive phenotype on benign prostate epithelial cells; however, this phenotype is
suppressed by cooverexpression of TIMP3. EZH2 knockdown markedly reduces the proteolytic activity of MMP-9, thereby
decreasing the invasive activity of prostate cancer cells. These results suggest that the transcriptional repression of the TIMP
genes by EZH2 may be a major mechanism to shift the MMPs/TIMPs balance in favor of MMP activity and thus to promote
ECM degradation and subsequent invasion of prostate cancer cells.
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Introduction
Metastasis—the spread of cancer cells from a primary site to
other parts of the body—is a common feature of malignant
tumors. The process of cancer metastasis consists of multiple,
sequential steps; cancer cells escape from the primary tumor, enter
the bloodstream, travel to distant sites, and extravasate to form
secondary tumor sites [1]. During metastasis, cancer cells invade
and migrate through the normal molecular constraints, such as the
extracellular matrix (ECM) [2]. The ECM, often referred to as
the connective tissue, is an organized network of extracellular
materials surrounding and supporting cells. The ECM is
composed of a wide variety of polysaccharides and proteins, such
as laminins, collagens, fibronectin, and proteoglycan, and plays an
integral role in determining the shape, development, and
biochemical function of cells [2]. The fabric of the ECM proteins
makes up the basement membrane (BM) that underlies the basal
surface of epithelial tissues and forms a physical barrier against
tumor invasion. Cancer cells are capable of degrading the ECM
barrier by using enzymes, resulting in dissolution of the BM. Most
prominent among the enzymes are the matrix metalloproteinases
(MMPs) [3].
MMPs are a large family of zinc-dependent endopeptidases and
responsible for degradation of the ECM [4]. MMPs have long
been known to be associated with physiological and pathological
processes such as tissue remodeling, wound healing, angiogenesis,
and cancer progression [5–8]. MMPs appear in latent proteins in
the cytosol (pro-MMPs) and undergo proteolytic processing to
yield the mature enzymes, which are, in turn, secreted and
associated with the cell surface and the ECM [9,10]. When
displayed at the cell surface, however, MMPs are inhibited by the
endogenous tissue inhibitors of metalloproteinases (TIMPs),
which directly bind to the catalytic domains of MMPs in a 1:1
stoichiometry [11]. Therefore, the balance between MMPs and
TIMPs is critical for eventual ECM remodeling and degradation.
The human genome encodes four TIMPs (TIMP1–TIMP4) that
are functionally redundant and inhibit 23 human MMPs [12]. In
many malignant tumors, expression of TIMPs is down-regulated,
consistent with their role as MMP inhibitors [13,14]. Suppression
of TIMP expression by antisense RNA confers oncogenicity on
Swiss 3T3 cells [15,16]. Conversely, overexpression of TIMPs
results in the inhibition of invasion and metastasis of cancer cells
[17–23]. These observations indicate that repression of TIMP
genes may be an important regulatory mechanism for cancer
progression, but the underlying mechanism is still not fully
understood.
EZH2 (polycomb group protein enhancer of zeste homolog 2) is
the catalytic subunit of the polycomb repressive complex 2 (PRC2)
[24,25] and is overexpressed in a variety of human cancers [26].
Early studies showed that high levels of EZH2 expression are
associated with invasion and metastasis of malignant tumors such
as breast and prostate cancers [27–31] and that EZH2
overexpression transforms the benign prostate cells RWPE-1
[32] and BPH1 [33] and the immortalized breast epithelial cells
[28]. Recently, EZH2 has also been found to regulate signaling
pathways associated with cellular metabolism such as the Ras
GTPase-activating protein DAB2IP [34,35] and the adrenergic
receptor-beta-2 ADRB2 [36], promoting cancer progression.
EZH2 appears to mediate transcriptional silencing by either
methylating lysine 27 in histone H3 (3meH3K27) [23,24] or
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30393recruiting DNA methyltransferases (DNMTs) to its target genes
that catalyze de novo DNA methylation [37]. However, recent
reports have also shown that H3K27 trimethylation by EZH2 is
not always associated with promoter DNA methylation for the
silencing of certain EZH2-target genes [38–41]. The functional
role of EZH2 in prostate cancer progression has been identified
by gene expression profilingo fR N Af r o mn o n t u m o r i g e n i c
human prostate epithelial cells overexpressing EZH2 [27].
However, the results were found not to alter significantly
expression levels of many metastasis–associated genes that were
identified by genetic profiling of human prostate cancer cells [42].
The nature of this discrepancy is unclear but might arise from
differences in expression levels of EZH2 in the prostate cancer
cells tested.
In this study, we investigated the role of EZH2 in activation of
MMPs to promote the invasion and metastasis of prostate cancer
cells. To identify the metastasis-associated genes regulated by
EZH2 in prostate cancer, mRNA expression in highly invasive
prostate cancer cells in which EZH2 expression was knocked down
was profiled using human metastasis PCR arrays. We found that
high levels of EZH2 expression during cancer progression induce
repression of TIMP genes (TIMP2 and TIMP3), leading to
increased activity of MMP-9 and thus to increased invasive
activity of prostate cancer cells. These results provide for the first
time evidence that EZH2 plays an active role in shifting the
MMPs/TIMPs balance towards MMPs and thereby promoting
metastasis of prostate cancer cells.
Results
EZH2 knockdown significantly reduces the invasive and
migratory activities of prostate cancer cells
To investigate whether high levels of EZH2 expression is
correlated with the invasive pheno t y p eo fp r o s t a t ec a n c e rc e l l s ,
we first determined protein levels of EZH2 in human prostate cell
lines (LNCaP, PC3, and DU145). Our Western blot analysis
showed that EZH2 levels are significantly elevated in the cancer
cell lines than in the benign human prostate epithelial cell line
RWPE-1 (Figure 1A). We then examined the invasive activity of
prostate cancer cells expressing different levels of EZH2 protein
using Transwell Boyden chamber assay. To this end, EZH2
expression was knocked down using two different EZH2-specific
shRNAs, sh1 or sh2 (Figure 1C, top). PC3 and DU145 cells were
highly invasive, compared with the benign RWPE-1 cells
( F i g u r e1 B ) .H o w e v e r ,E Z H 2k n o c k down significantly decreased
invasiveness of the prostate cancer cells (Figure 1C, middle); only
18,20% of the prostate cancer cells infected with lentivirus
expressing EZH2 targeting shRNA penetrated the BME
membrane in the chamber (sh1 and sh2), compared with those
cells infected with the control (NT, nontargeting shRNA)
lentivirus (Figure 1C, bottom). On the contrary, overexpression
of EZH2 conferred an invasive phenotype on RWPE-1 cells
(Figure 1D, WT); however, RWPE-1 cells overexpressing a
mutant EZH2 protein (EZH2-H689A) with significantly reduced
HMT activity [44] did not display invasive activity (Figure 1D,
H 6 8 9 A ) .B e c a u s eE Z H 2p l a y sa na c t i v er o l ei np r o s t a t ec a n c e r
invasion (Figures 1C and 1D), we further examined the migratory
activity of DU145 cells using the wound-healing migration assay
(Figure 1E, top). We found that DU145 cells fill ,80% and
,50% of the wounded areas before (NT) and after (sh1)
knockdown of EZH2 expression, respectively, at 24 h after
scratching (Figure 1E, bottom). These results strongly suggest
that high levels of EZH2 expression promote invasion and
migration of prostate cancer cells.
Identification of the downstream target genes of EZH2
associated with metastasis of prostate cancer
To identify metastasis-associated genes whose expressions are
regulated by EZH2, we investigated gene expression changes in
invasive prostate cancer cells after EZH2 knockdown. Expression
of different mRNAs in prostate cancer cells was assessed by using
the human tumor metastasis RT
2 Profiler
TM PCR Array (PAHS-
028D) designed to represent 84 genes known to be involved in
metastasis (Figures 2A and 2B). The results showed that expression
of 12 and 32 genes is altered .2-fold in DU145 (Table S1) PC3
(Figures S1A and S1B and Table S2) cells, respectively, by
knockdown of EZH2 expression. Among those genes, TIMP3 was
found to be the gene that is most highly upregulated in both
DU145 and PC3 cells (Figures 2B and S1B), leading to the
hypothesis that TIMP3 may be a primary target for repression by
EZH2. To test this hypothesis, we examined protein levels of
TIMP3 and EZH2 by immunohistochemistry using anti-EZH2
and anti-TIMP3 antibodies (Figure 2C). As shown in the
immunostaining images, TIMP3 protein levels were high in
normal prostate tissues (Figures 2C-e and 2C-f), but barely
detectable in prostate cancer tissues (Figures 2C-g and 2C-h).
Similar results were obtained by RT-PCR analysis showing that
TIMP3 mRNA levels are markedly decreased in PC3 and DU145
cells, compared with the RWPE-1 cells (Figure S1C). In contrast,
EZH2 protein levels were very high in prostate cancer tissues
(Figures 2C-c and 2C-d) compared with normal prostate tissues
(Figures 2C-a and 2C-b). These observations suggest that
expression of TIMP3 and EZH2 is inversely correlated, probably
due to downregulation of TIMP3 expression by EZH2.
Downregulation of TIMP3 expression by EZH2 in prostate
cancer cell lines
To investigate further the transcriptional repression of TIMP3
expression by EZH2, we quantitatively determined TIMP3 mRNA
and protein levels in three prostatec a n c e rc e l ll i n e s( L N C a P ,P C 3 ,
and DU145) with and without knockdown of EZH2 expression.
TIMP3 mRNA levels were found to be ,10–13-fold higher in the
cancer cells treated with EZH2-specific shRNA (sh1) than control
cells untreated with the shRNA (Figure 3A), and as a result, TIMP3
protein levels were significantly increased by knockdown of EZH2
expression (Figure 3B). In contrast, overexpression of the functional
EZH2 (WT), but not of the mutant EZH2 protein (H689A), was
shown to decrease TIMP3 mRNA and protein levels in RWPE-1
cells (Figure 3C). Down-regulation of TIMP3 expression by EZH2
was also confirmed by immunostaining of TIMP3 in DU145 cells
infected with EZH2-specific shRNA lentivirus (sh1) or control
(nontargeting shRNA) lentivirus (NT) (Figure 3D). TIMP3 protein
levelswerelowin DU145 cells(Figure 3D-c)butsignificantlyelevated
by knockdown of EZH2expression (Figure 3D-h).Thus, TIMP3 may
be a target of EZH2 for repression in prostate cancer cells.
Epigenetic silencing of TIMP3 expression by EZH2
EZH2 is a component of PRC2 that catalyzes trimethylation of
H3K27 (3meH3K27) [24,25]. To explore the underlying mech-
anism of the epigenetic repression of TIPM3 by EZH2, we
investigated effects of the histone methylation inhibitor 3-Deaza-
naplanocin A (DZNep) on expression of TIMP3. DZNep
treatment resulted in decreased levels of TIMP3 protein
(Figure 4A), probably by causing derepression of TIMP3
expression (Figure 4B). Moreover, the invasive potential of PC3
cells was ,5-fold decreased by DZNep treatment (Figure 4C).
To study further the molecular mechanism of the transcrip-
tional repression of TIMP3 expression by EZH2, we performed
Activation of MMPs by EZH2
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3meH3K27 antibodies.BecausePcGproteinsarerecruitedto DNA
via the DNA-binding protein YY1 [45], the immunoprecipitated
DNAwas analyzedbyPCRwith theprimersetsdesigned to amplify
regions containing the YY1-binding sites in the TIMP3 promoter
(Figure 5A). The results indicate that: 1) EZH2 binds to the TIMP3
promoter and catalyzes trimethylation of H3K27 (3meH3K27)
(Figures 5B and 5C), but does not bind to the GAPDH promoter,
served as a negative control (Figure 5C); 2) RNA polymerase II
(RNAP II) binds strongly to the GAPDH promoter but has no
appreciable binding to the TIMP3 promoter (Figure 5C). These
results suggest that EZH2-mediated trimethylation of H3K27
prevents RNAP II from binding to the TIMP3 promoter and
thereby results in transcriptional silencing of the gene.
We next determined whether H3K27 trimethylation is coupled
with promoter DNA methylation for the repression of TIMP3, we
treated PC3 cells with DZNep or the DNA methylation inhibitor
5-Aza followed by ChIP analysis. EZH2 knockdown or DZNep
treatment markedly inhibited both H3K27 trimethylation and
DNA methylation (MeCP2, methyl CpG binding protein 2) of the
TIMP3 promoter; in contrast, 5-Aza treatment inhibited only
DNA methylation but had no significant effect on H3K27
trimethylation of the promoter (Figure 5D). Furthermore,
treatment of PC3 cells with DZNep or 5-Aza resulted in
derepression of TIMP3 expression to almost the same degree
(Figure 5E). Thus, these results suggest that transcriptional
repression of the TIMP3 gene occurs through the EZH2-mediated
H3K27 trimethylation and subsequent DNA methylation.
Epigenetic silencing of TIMP2 expression by EZH2
We next investigated whether, like TIMP3, other three TIMPs
(TIMP1, TIMP2 and TIMP4) are transcriptionally repressed by
Figure 1. High levels of EZH2 promote invasion and migration of prostate cancer cells. (A) Western blot analysis of EZH2 expression in the
benign prostate cell line RWPE-1 and the malignant prostate cancer cell lines LNCaP, DU145, and PC3 (top). Actin was used as an internal control. The
protein bands were quantified using Quantity One software (Bio-Rad) (bottom). (B) Invasion assay of RWPE-1, PC3 and DU145 cells. Cell invasiveness
was assessed by the invasion of cells through BME-coated inserts in the Transwell Boyden chamber (top). The invasion rate was determined by
counting the cells that migrated through the inserts and expressed as the percentage relative to control (RWPE-1, set to 100%) (bottom). Each bar
represents the mean 6 s.e of five fields counted. (C) Western blot analysis of EZH2 expression in PC3 and DU145 cells after an infection with EZH2-
specific shRNA lentivirus (sh1 or sh2; two different EZH2-specific shRNAs) or with non-treated shRNA (NT, control) lentivirus (top). Invasion assayo f
PC3 or DU145 cells after an infection with EZH2-specific shRNA (sh1 or sh2) or control (NT) lentivirus (middle). Representative fields of invaded and
stained cells are shown (middle). Each bar represents the mean 6 s.e of five fields counted (bottom). (D) Western blot analysis of overexpression of
wild-type (WT) and mutant (H689A, enzymatically inactive) EZH2 proteins in RWPE-1 cells infected with EZH2 (WT)-GFP, EZH2 (H689A)-GFP, or control
(GFP vector) lentivirus. EZH2 proteins were expressed from the CMV promoter (left). Invasion assay of RWPE-1 cells infected with EZH2 (WT)-GFP,
EZH2 (H689A)-GFP, or control (GFP vector) lentivirus (right). (E) Wound healing assay of DU145 cells infected with EZH2-specific shRNA (sh1) or
control shRNA (NT) lentivirus. Images were taken before (0 h) and after wound (24 h) (top). The results were expressed as the percentage of the
remaining area determined by normalizing the area of wound after 24 h to the initial wound area at 0 h (set to 100%). Each bar represents the mean
6 s.e of five fields measured (bottom).*P ,0.05, ** p,0.005 *** p,0.001 (as compared with control values).
doi:10.1371/journal.pone.0030393.g001
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regulated by EZH2, whereas TIMP4 was repressed when EZH2
expression is knocked down (Figure 6). In contrast, TIMP2
expression was significantly increased by EZH2 knockdown, but
was not increased when the mutant EZH2 protein (EZH2-H689A)
is expressed. Our ChIP studies show that TIMP2, like TIMP3, is
also subject to EZH2-mediated histone methylation and subse-
quent promoter DNA methylation (Figure 7). Down-regulation
of the TIMP2 gene in prostate cancer cells was shown to be
associated with promoter methylation [13], suggesting that
epigenetic regulatory factors, such as HDAC and DNMT, may
be involved in regulation of TIMP2. Our results show that the
epigenetic modifier EZH2 may be the factor that mediates
epigenetic inactivation of TIMP2.
Transcriptional repression of TIMP3 by EZH2 promotes
invasion of prostate cancer cells
To assess the functional link between the downregulation of
TIMP3 byEZH2(Figure 3) and the decreased invasivephenotype of
prostate cancer cells by EZH2 knockdown (Figures 1C and 1D), we
overexpressed EZH2 and TIMP3 separately or together inRWPE-1
cells (Figure 8A) and examined the invasive activity of the cells
using Transwell Boyden chamber assay (Figure 8B). The invasive
phenotype ofRWPE-1cellswasinduced byEZH2overexpressionas
observed above (Figure 1D), but it was significantly suppressed by
cooverexpression of TIMP3 (Figure 8B), providing direct evidence
that the repression of TIMP3 by EZH2 results in increased invasive
activity of prostate cancer cells.
MMP-2 and MMP-9 are known to be the prominent MMPs
responsible for ECM degradation, and thus we tested whether
enzymatic activity of these two MMPs is regulated by EZH2 using
gelatin zymography assay. MMP-2 activity was found not to be
changed significantly by EZH2 knockdown. However, MMP-9
activity was decreased by ,28% in PC3 cells and ,50% in
DU145 cells, respectively, treated with EZH2-specific shRNA,
compared with control cells (NT) (Figure 8C). Taken together,
these results suggest that EZH2-mediated transcriptional repres-
sion of TIMP3 directly leads to activation of MMP-9.
Discussion
The balance between MMPs and TIMPs is a critical parameter
for the degradation of ECM and thus a crucial step for cancer
invasion and metastasis. In this study, we show that aberrant
upregulation of EZH2 expression in prostate cancer cells shift this
balance towards MMPs and thereby promote degradation of the
Figure 2. Identification of the downstream target genes of EZH2 associated with metastasis of prostate cancer. (A)R T
2 profiler PCR
array for Human Tumor Metastasis genes in DU145 cells after an infection with EZH2-specific shRNA or control (NT) lentivirus. The scatter plot of the
test vs control samples indicates the validity of the experiment. (B) 12 genes whose expressions are highly affected by EZH2 knockdown are shown
(also see Tables S1 and S2). Total RNA was isolated from DU145 cells after an infection with EZH2-specific shRNA or control (NT) lentivirus and
processed for PCR array (C) Immunofluorescence images of normal prostate (Normal 1 and Normal 2) and prostate tumor tissue sections (PCa1 and
PCa2), using anti-EZH2 antibody (green) and anti-TIMP3 antibody (red). Nuclei were stained with DAPI (blue).
doi:10.1371/journal.pone.0030393.g002
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genes (TIMP2 and TIMP3). TIMP2 and TIMP3, compared with
TIMP1 and TIMP4, inhibit a broad spectrum of MMPs and
several of disintegrin-metalloproteinases, ADAMs and ADAMTSs
[12]. Furthermore, TIMP3 is the only member of the TIMP
family that tightly binds to ECM and thus is implicated in disease
pathogenesis [9,10]. TIMP3 also has an inhibitory effect on
angiogenesis by blockage of VEGF binding to VEGF receptor-2
[46] and an ability to promote apoptosis [47–49]. Therefore, the
transcriptional repression of TIMP2 and TIMP3 by EZH2 likely
enhances ECM degradation and angiogenesis but reduces
apoptotic activity, favoring cancer cell invasion and metastasis.
The presence or elevated expression of some of MMPs is
positively associated with cancer progression [3,50]. Our metas-
tasis PCR array analysis shows that some MMP genes, such as
MMP7 and MMP13, in PC3 cells were markedly downregulated
by knockdown of EZH2 expression (Figure S1). Thus, EZH2
seems to act as an activator, rather than a repressor, of the
Figure 3. Expression of TIMP3 is downregulated by EZH2 in prostate cancer cells. (A) qRT–PCR analysis of expression of TIMP3 in the
prostate cancer cells (LNCaP, DU145, and PC3) after an infection with EZH2-specific shRNA (sh1) or control shRNA lentivirus (NT). *P ,0.05, ** p,0.005
(as compared with control (NT)). (B) Western blot analysis of endogenous levels of EZH2 and TIMP3 protein in prostate cancer cells (LNCaP, DU145,
and PC3) infected with EZH2-specific shRNA (sh1) or control shRNA virus (NT). Actin was used as an internal control. (C) Western blot (top) and qRT–
PCR (bottom) analyses of expression of EZH2 and TIMP3 in the benign prostate RWPE-1 cells after an infection with EZH2 (WT)-GFP, EZH2 (H689A)-
GFP, or control (GFP vector) lentivirus. Actin was used as an internal control. *P ,0.05, ** p,0.005 (as compared with control (vector)). The solid arrow
indicates EZH2-GFP expressed from the CMV promoter, the dotted arrow indicates endogenous EZH2. (D) Immunostaining of EZH2 and TIMP3
expressed in DU145 cells infected with EZH2-specific shRNA (sh1) or control (NT) lentivirus, using anti-EZH2 antibody (green) and anti-TIMP3 antibody
(red). Nuclei were stained with DAPI (blue). The merged images were also shown (EZH2/TIMP3 and DAPI/TIMP3).
doi:10.1371/journal.pone.0030393.g003
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observed in DU145 cells, perhaps due to different genetic
backgrounds between the two cell lines [51]. While the transcrip-
tionalregulationofMMPgenesbyEZH2,whichwasout ofscopeof
this study, is currently under investigation, our results support the
possibility that overexpression of EZH2 in metastatic prostate
cancer cells may elevate overall MMP activity both by decreasing
the levels of TIMPs (TIMP2 and TIMP3) and by increasing the
levels of some MMPs, such as MMP-9.
Promoter DNA methylation is the most common epigenetic
modification associated with gene silencing in cancer. EZH2
appears to recruit DNMTs to its target genes, resulting in
methylation of adjacent CpG islands and subsequent gene
silencing [37]. In this model, EZH2-mediated H3K27 methylation
may be a prerequisite for promoter DNA methylation. Our results
support this idea, as we have observed that TIMP2 and TIMP3,
like other EZH2 target genes such as MSMB [31], RUNX3 [52],
and SLIT2 [39], are silenced through histone (H3K27) methyla-
tion followed by DNA methylation (Figures 5 and 7). However,
promoter DNA methylation is not always required for repression
of the EZH2 target genes. For example, EZH2-mediated silencing
of the E-cadherin gene occurs through H3K27 methylation but
does not require promoter DNA methylation [38]. In addition,
H3K27 trimethylation is not associated with promoter DNA
methylation for silencing of a substantial number of EZH2 target
genes in prostate cancer [41]. Therefore, further studies are
required to distinguish these mechanisms.
In order for cancer cells to metastasize, they must break free
from the normal physical barriers, to migration and invasion, such
as ECM and cell-cell adhesion. Moreover, degradation of the
ECM releases signaling molecules associated with the ECM, such
as growth factors and cytokines, that significantly influence
metastasis [53]. Thus, the ECM degradation by MMPs is of
pivotal importance for not only eliminating the barriers but also
making the signaling molecules accessible to cancer cells. As
demonstrated in this study, EZH2, which acts as a potential
oncogene in various malignancies, plays an active role in the
upregulation of MMP activity and promote ECM degradation and
subsequent invasion of prostate cancer cells, providing a novel
insight into the role of EZH2 in prostate cancer metastasis.
Materials and Methods
Cell culture
All cell lines used in this study were obtained from the American
Type Culture Collection (ATCC; Rockville, MD). PC3, DU145
and LNCaP cells were cultured in RPMI 1640 with 10% FBS and
penicillin/streptomycin at 37uC in a humidified atmosphere of 5%
CO2. The RWPE-1 cells were cultured in keratinocyte serum-free
medium (K-SFM) containing 50 mg/ml bovine pituitary extract
and 5 ng/ml epidermal growth factor as described previously [43].
The cells were fed with fresh growth medium every 3 days, and at
confluence, they were subcultured at a 1:4 ratio using trypsin-
EDTA (0.05%).
Lentiviral infection
Lentiviral transduction was used for EZH2 knockdown and
EZH2 overexpression in prostate cancer cells. Lentiviral expression
vectors for GFP (green fluorescent protein; as a control), wild-type
EZH2-GFP, and mutant EZH2 (H689A)-GFP were constructed by
Figure 4. Repression of TIMP3 expression by histone methylation (3meH3K27) in prostate cancer cells. (A) Western blot analysis of
endogenous levels of EZH2, TIMP3 and 3meH3K37 in the prostate cancer cells (PC3 cell) after treatment with DZNep (5 mM) or DMSO (control) for 2
days. Actin was used as an internal control. (B) qRT–PCR analysis of expression of TIMP3 in PC3 cells treated with DZNep (5 mM) or DMSO (control). (C)
Invasion assay of PC3 cells treated with DZNep (5 mM) or DMSO (control).
doi:10.1371/journal.pone.0030393.g004
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(Invitrogen). We obtained lentiviral short hairpin RNAs (shRNAs)
specific for EZH2 from Sigma-Aldrich (MISSIONH shRNA).
Biologically active shRNAs were generated from the pLKO.1-puro
vector, utilizing the Polymerase III U6-RNA promoter. The
shRNA sequences for EZH2 knockdown were 59CCGGTAT-
GATGGTTAACG GTGATCACTGAGTGATCACCGTTAA-
CCATCATATTTTTG-39 (TRCN18365, sh1) and 59-CCGGG-
CTAGGTTAATTGGGACCAAACTCGAGTTTGGTCCCAA-
TTAACCTAGCTTTTTG-39 (TRCN40074, sh2). Because these
two shRNAs are equally effective in suppression of EZH2 mRNA
expression, we used EZH2-specific shRNA1 (sh1) in some of our
experiments. For viral production, 293T cells were cotransfected
with pLKO.1, pLenti4-EZH2-WT, pLenti4-EZH2-H689A or
pLKO.1-EZH2-specific shRNA, and packaging plasmids (psPAX2
and pCMV-VSV-G) using CalPhos Mammalian Transfection Kit
(Clontech). The virus-containing supernatants were collected 48–
72 h after transfection and aliquoted to be stored at 280uC.
Quantitative real-time PCR
Expression of TIMP and GAPDH mRNA was measured by real-
time quantitative PCR using SYBR Green PCR Mastermix
(Quanta biosciences). Total RNA was isolated from prostate cancer
cells using Trizol Reagent (Invitrogen). 2 mg of total RNA was used
for reverse transcription reactions using qScript cDNA SuperMix
Kit following the manufacturer’s instructions (Quanta biosciences).
Results shown were a representative of three independent
experiments. The primers used in this study are listed in Table S3.
Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS)
supplemented with protease inhibitor cocktail (Roche Applied
Science) or lysed directly in 26 SDS-PAGE sample buffer, and
subjected to Western blot analysis using antibodies against EZH2
(BD Biosciences, 612666), TIMP2 (Millipore Inc., MAB3310),
TIMP3 (Abcam, ab39184), 3meH3K27 (Millipore Inc., 07-449),
MeCP2 (Millipore Inc., 07-013), RNA polyersase II (Millipore Inc.,
05-623), and Actin (Sigma-Aldrich, A2066). Protein bands were
visualized using West Pico chemiluminescent detection system
(Pierce) and subjected to densitometry analysis using the ChemiDoc
XRS system with Quantity One software (Bio-Rad Laboratories).
Immunostaining for EZH2 and TIMP3
4–5-mm-thick, formalin-fixed, paraffin-embedded human pros-
tate cancer and normal sections were purchased from Cybrd and
Figure 5. Transcriptional silencing of TIMP3 by EZH2. (A) Schematic representation of the promoter region of the TIMP3 gene. The bent arrow
represents the transcription start sites (+1). The lines below the TIMP3 locus represent the regions amplified by PCR. (B–C) Immunoprecipitated DNA was
analyzed by PCR with specific primer sets (also see Table S3). Chromatin obtained from PC3 (B) and DU145 (C) cells were immunoprecipitated using
antibodies to EZH2, trimethyl-histone H3K27 (3meH3K27), RNA Polymerase II (Pol II), and IgG. The immunoprecipitated DNA was analyzed by PCR with the
primer sets to amplify the region 4 in Figure 5A. The GAPDH promoter was used as a negative control. Each ChIP experiment was repeated at least three
times and a representative experiment is shown. (D) Epigenetic regulation of TIMP3 expression in PC3 cells. ChIPassay was carriedout using the antibodies
to EZH2, 3meH3K27, MeCP2, RNAP II (Pol II), and IgG control after treatment with DZNep (1 mM), 5-Aza (10 mM), DMSO (control), or EZH2-specific shRNA
(shRNA1). The immunoprecipitated DNA was analyzed by PCR with the primer sets to amplify the region 4 in Figure 5A. (E) qRT–PCR analysis of expression
of TIMP3 in PC3 cells after treatment with DZNep (1 mM), 5-Aza (10 mM), or DMSO (control) for 2 days. The experiments were repeated at least twice and
results were expressed as a ratio of TIMP2 or TIMP3 mRNA to GAPDH mRNA control. *P ,0.05, ** p,0.005 (as compared with control (DMSO)).
doi:10.1371/journal.pone.0030393.g005
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chamber slides (Nunc) and infected with either control or EZH2-
specific shRNA lentivirus. After cultivating for 2–4 days, the cells
w e r ef i x e dw i t hc o l dm e t h a n o la nd permeabilized with buffer
containing 1% BSA, 10% normal goat serum, 0.3 M glycine, and
0.1% PBS-Tween for 1 h. The resulting cells were incubated
with anti-TIMP3 and anti-EZH2 antibodies at 4uCo v e r n i g h t .
After washing, they were incubated with Alexa FluorH 594 goat
anti-rabbit IgG and Alexa FluorH 488 goat anti-mouse IgG at a
1/1000 dilution for 1 h. After mounting with mounting
medium containing DAPI (Vector Labs, H-1200), the cells were
photographed using a fluorescence microscope (Olympus
Imaging America Inc, IX71 microscope).
Cell invasion and migration assays
Cell invasion assay was performed using the cell invasion kit
(Transwell Boyden’s chamber with TranswellH Permeable Support
Inserts Coated with CultrexH BME (basement membrane extract),
Corning Costar) according to the manufacture’s instruction. In
brief, serum-starved RWPE-1, DU145, or PC3 cells (2610
5 cells/
Figure 6. Expression of TIMPs is differently regulated by EZH2. (A–C) qRT–PCR analysis of expression of TIMP genes (A, TIMP1; B, TIMP2; C,
TIMP4) in the prostate cancer cells (LNCaP, DU145, and PC3) after an infection with EZH2-specific shRNA (sh1) or control shRNA lentivirus (NT).
*P ,0.05, ** p,0.005 (as compared with control (NT)). (D–F) qRT–PCR analysis of expression of TIMP genes (D, TIMP1; E, TIMP2; F, TIMP4) in the
benign prostate cell line RWPE-1 after an infection with EZH2 overexpression lentivirus (WT or H689A) or control virus for 4 days. Results were
expressed as a ratio of TIMP mRNAs to GAPDH mRNA control. *P ,0.05, ** p,0.005 (compared with control (GFP)).
doi:10.1371/journal.pone.0030393.g006
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medium containing 10% fetal bovine serum was added to the
l o w e rc h a m b e ra n di n c u b a t e di n5 %C O 2 at 37uC for 24 h.
Nonmigrating cells were gently removed from the upper surface
of the filter with a cotton swab; migrating cells attached on
t h el o w e rs u r f a c eo ft h ef i l t e rw e r ef i x e da n ds t a i n e dw i t h
hematoxylin for counting. For the wound-healing migration
assay, DU145 cells were seeded at 70% confluence into 6-well
culture dishes and, 24 hours later, infected with EZH2-specific or
control shRNA lentivirus. After the cells grew to confluence,
scratch wounds were made on the confluent monolayers using
sterile pipette tips. Afterward, the culture medium was replaced
with fresh, complete medium and cells were incubated at 37uC
for 24 h and then fixed and photographed. Cell migration was
monitored using Olympus IX71 microscope, cell-migration areas
were calculated with DP2-BSW application software (Olympus
Imaging America Inc.).
Chromatin immunoprecipitation (ChIP) assay
Chromatin was isolated from prostate cancer cell lines using the
ChIP assay kit (Milipore Inc.) and precipitated with anti-EZH2,
anti-3meH3K27, anti-MeCP2, or anti-RNA polymerase II
antibodies. Immunoprecipitated DNA was PCR-amplified with
the primer sets covering specific regions of the TIMP2 and TIMP3
promoters (Table S3). To amplify the DNA within a linear range
of amplification for each gene, PCR was performed with
different number of cycles or with a serial dilution of input
DNA, and all results shown fall within this range. PCR products
were run on agarose gels and visualized by ethidium bromide
staining.
Zymography assay
Gelatin zymography assay was performed using confluent
prostate cells, which were maintained in serum-free media for
24 h and concentrated using an Amicon Ultra 10 k (Millipore).
Equal amounts of concentrated media were mixed with the SDS
sample buffer which did not contain b-mercaptoethanol and
loaded onto SDS-PAGE gels containing 0.2% gelatin (Sigma).
After electrophoresis, gels were washed three times for 20 min at
room temperature with renaturing buffer (2.5% Triton X-100).
They were then equilibrated in developing buffer (50 mM Tris-
HCl pH 7.5, 0.15 M NaCl, 10 mM CaCl2 and 0.05% NaN3)a t
room temperature with gentle agitation for 20 min. After
removing the developing buffer, the gels were incubated with
fresh developing buffer at 37uC for 24 h. Finally, the gels were
washed with distilled water, stained with 0.05% Coomassie
Brilliant Blue for 1 h, and destained with destaining solution
(45% methanol and 10% acetic acid) for 3 h.
Figure 7. Transcriptional silencing of TIMP2 by EZH2. (A) Schematic representation of the promoter regions of the TIMP2 gene. The bent
arrow represents the transcription start sites (+1). The lines below the TIMP2 locus represent the regions amplified by PCR using primer sets (set 1, set
2, and set 3 in (B); set 2 in (C) and (D)) designed to amplify regions containing the YY1-binding sites (see Table S3). (B–C) Chromatin
immunoprecipitation (ChIP) experiments were performed with chromatin isolated from PC3 (B) and DC145(C) cells using antibodies to EZH2,
3meH3K27, and IgG. Results of our ChIP in both PC3 and DU145 cells are very similar to each other. Shown are ChIP results in DU145 cells. (D)
Epigenetic regulation of TIMP2 expression in PC3 cells. ChIP assay was carried out using the antibodies to EZH2, 3meH3K27, MeCP2, RNAP II (Pol II),
and IgG control after treatment with DZNep (1 mM), 5-Aza (10 mM), DMSO (control), or EZH2-specific shRNA (shRNA1). (E) qRT–PCR analysis of
expression of TIMP2 in PC3 cells after treatment with DZNep (1 mM), 5-Aza (10 mM), or DMSO (control) for 2 days. The experiments were repeated at
least twice and results were expressed as a ratio of TIMP2 mRNA to GAPDH mRNA control. *P ,0.05, ** p,0.005 (as compared with control (DMSO)).
doi:10.1371/journal.pone.0030393.g007
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The anti-actin antibody (A2066), 5-Aza-29-deoxycytidine (5-Aza,
A3656), and EZH2 specific-shRNAs were obtained from Sigma-
Aldrich. The anti-TIMP2 (MAB3310), anti-3meH3K27 (07-449),
anti-MeCP2 (07-013), anti-RNA polymersase II (05-623) antibodies
were purchased from Millipore. The anti-EZH2 antibody (612666)
was obtained from BD Biosciences. 3-Deazaneplanocin A (DZNep,
13828) was purchased from Cayman. Anti-TIMP3 (ab39184) was
obtained from Abcam.
Supporting Information
Figure S1 Identification of the downstream target genes
of EZH2 associated with metastasis of prostate cancer.
(A)R T
2 profiler PCR array for Human Tumor Metastasis genes in
PC3 cells after an infection with EZH2-specific shRNA or control
(NT) lentivirus. The scatter plot of the test vs control samples
indicates the validity of the experiment. (B) 21 genes whose
expressions are highly affected by EZH2 knockdown are shown
(also see Tables S1 and S2). Total RNA was isolated from PC3
cells after an infection with EZH2-specific shRNA or control (NT)
lentivirus and processed for PCR array. (C) qRT-PCR analysis to
determine endogenous levels of TIMP3 mRNA in the benign
prostate cell line RWPE-1 and the malignant prostate cancer cell
lines PC3 and DU145. Results were expressed as a ratio of the
TIMP3 mRNA to the house keeping gene GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) mRNA control. *P ,0.05,
** p,0.005 *** p,0.001 (as compared with control values).
(EPS)
Table S1 List of genes differentially expressed in DU145
cells after EZH2 knockdown using a Human Tumor
Metastasis Real-time PCR Array.
(DOC)
Figure 8. Transcriptional repression of TIMP3 by EZH2 promotes invasion of prostate cancer cells. (A) Western blot analysis of EZH2 and
TIMP3 expression in RWPE-1 cells after an infection with the indicated combinations of lentivirus expressing EZH2, TIMP3 and control virus. (B)
Invasion assay of RWPE-1 cells after an infection with the indicated combinations of lentivirus expressing EZH2, TIMP3 and control virus. Top: a,
EZH2(2)/TIMP3(2); b, EZH2(2)/TIMP3(+); c, EZH2(+)/TIMP3(2); d, EZH2(+)/TIMP3(+). (C) Gelatin zymographic assay for MMP-2 and MMP-9 activity in
PC3 and DU145 cells infected with EZH2-specific shRNA (sh1) or control shRNA virus (NT). The upper and lower bands indicate active MMP-9 (92 kDa)
and active MMP-2 (62 kDa), respectively. Zymographic band intensities were quantified by densitometry using Quantity One software (Bio-Rad). Each
bar represents the mean 6 s.e of three fields counted. *P ,0.05, ** p,0.005, *** p,0.001 (as compared with control (NT)).
doi:10.1371/journal.pone.0030393.g008
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cells after EZH2 knockdown using a Human Tumor
Metastasis Real-time PCR Array.
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Table S3 Primers for RT-PCR and ChIP analyses.
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